Lucatumumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lucatumumab
Accession Number
DB06360
Type
Small Molecule
Groups
Investigational
Description
Not Available
Synonyms
Not Available
External IDs
CHIR-12.12 / HCD-122 / HCD122
Categories
UNII
P0EP9VFC4R
CAS number
903512-50-5
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).

Pharmacodynamics
Not Available
Mechanism of action

HCD122 is a fully human, antagonist antibody that targets the CD40 antigen. HCD122 binds to tumor cells that express CD40 and antagonizes (prevents) CD40 ligand-mediated growth and survival of malignant B cells. Based on preclinical data, HCD122 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes HCD122 a drug candidate with potential for the treatment of B-cell malignancies.

TargetActionsOrganism
UTumor necrosis factor receptor superfamily member 5Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Lucatumumab.
AbituzumabThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Lucatumumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Lucatumumab.
AducanumabThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Lucatumumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lucatumumab.
AlirocumabThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Lucatumumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Lucatumumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentFollicular Lymphoma (FL)1
1CompletedTreatmentMultiple Myeloma (MM)1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2CompletedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Receptor for TNFSF5/CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion.
Gene Name
CD40
Uniprot ID
P25942
Uniprot Name
Tumor necrosis factor receptor superfamily member 5
Molecular Weight
30618.76 Da

Drug created on March 19, 2008 10:27 / Updated on November 02, 2018 06:16